<DOC>
	<DOCNO>NCT01935492</DOCNO>
	<brief_summary>An open randomized phase III study compare 8 continuous cycle chemotherapy 8 cycle intermittent ( 2 time 4 cycle ) chemotherapy first line treatment , combination bevacizumab , second line treatment patient HER2/neu negative , incurable , metastatic unresectable locally advanced breast cancer .</brief_summary>
	<brief_title>8 Continuous v 8 Intermittent Cycles First Second Line HER2/Neu Neg Metastatic Breast Cancer</brief_title>
	<detailed_description>The primary goal non-inferiority trial determine result obtain intermittent chemotherapy regimen ( 2 x 4 cycle paclitaxel ) inferior result continuous chemotherapy regimen ( 8 cycle paclitaxel ) , combine bevacizumab first line treatment patient HER2/neu negative , incurable , metastatic unresectable locally advanced breast cancer .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Female patient ≥ 18 year old . Patients HER2/neu negative , incurable , metastatic unresectable locally advanced breast cancer , candidate chemotherapy . Patients measurable evaluableonly ( RECIST 1.1 ) Documented Estrogen Receptor ( ER ) / Progesteron Receptor ( PR ) status . HER2/neunegative disease Patients ECOG Performance Status ≤ 2 . Life expectancy &gt; 12 week . Signature Informed Consent Form Previous chemotherapy HER2/neu negative , incurable , metastatic unresectable locally advanced breast cancer . Prior hormonal therapy HER2/neu negative , incurable , metastatic unresectable locally advanced breast cancer discontinue 1 week start study treatment . Prior adjuvant/neoadjuvant chemotherapy within 6 month prior first study treatment . However , prior adjuvant/neoadjuvant chemotherapy taxane base , patient exclude receive last chemotherapy within12 month prior first study treatment . Prior radiotherapy cover 30 % marrowbearing bone . Patients receive recent radiation therapy recover significant ( Grade ≥ 3 ) acute toxicity prior study treatment . Prior therapy bevacizumab , sorafenib , sunitinib , VEGF pathwaytargeted therapy . Chronic daily treatment aspirin Chronic daily treatment corticosteroid , exception inhale steroid . Current recent treatment another investigational drug participation another investigational study . Inadequate bone marrow , liver , renal function INR &gt; 1.5 aPTT &gt; 1.5 x ULN within 7 day prior first study treatment . Known CNS disease , except treat brain metastasis . Patients concurrent active malignancy Pregnant lactate Women childbearing potential use effective , nonhormonal mean contraception Major surgical procedure ( include open biopsy ) within 28 day prior first study treatment Core biopsy minor surgical procedure , within 7 day prior day 1 . Significant vascular disease within 6 month prior day 1 . Any previous venous thromboembolism &gt; CTC Grade 3 . History haemoptysis History evidence inherit bleed diathesis coagulopathy risk bleeding . Uncontrolled hypertension Clinically significant ( i.e . active ) cardiovasculair disease LVEF MUGA ECHO &lt; 50 % . History abdominal fistula , Grade 4 bowel obstruction GI perforation , intraabdominal abscess within 6 month randomization . Serious nonhealing wound , peptic ulcer bone fracture . Known hypersensitivity study drug excipients . Hypersensitivity Chinese hamster ovary cell product recombinant human humanize antibody . Psychiatric illness , physical examination laboratory finding may interfer protocol</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>metastatic breast cancer</keyword>
	<keyword>HER2/neu negative</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>bevacizumab</keyword>
	<keyword>liposomal doxorubicine</keyword>
	<keyword>capecitabine</keyword>
</DOC>